Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Mayo Clinic Proceedings|July 10, 2017
Prediction of Response to Targeted Treatment in Rheumatoid ArthritisC A Wijbrandts, P P Tak
Annals of the Rheumatic Diseases|October 30, 2007
Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of responseR M Thurlings, K Vos, C A Wijbrandts, et al.
Annals of the Rheumatic Diseases|January 17, 2009
TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockadeA W R van Kuijk, C A Wijbrandts, M Vinkenoog, et al.
Annals of the Rheumatic Diseases|April 15, 2008
Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone lossC A Wijbrandts, R Klaasen, M G W Dijkgraaf, et al.
Annals of the Rheumatic Diseases|November 29, 2007
Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patientsT C van der Pouw Kraan, C A Wijbrandts, L G van Baarsen, et al.
Annals of the Rheumatic Diseases|August 30, 2008
Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritisC A Wijbrandts, S I van Leuven, H D Boom, et al.
Arthritis and Rheumatism|September 30, 2006
CTLA-4IG suppresses reactive oxygen species by preventing synovial adherent cell-induced inactivation of Rap1, a Ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cellsP H J Remans, C A Wijbrandts, M E Sanders, et al.
Annals of the Rheumatic Diseases|July 8, 2009
Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort studyG M Bartelds, C A Wijbrandts, M T Nurmohamed, et al.
Annals of the Rheumatic Diseases|March 24, 2012
Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritisR Klaasen, M M J Herenius, C A Wijbrandts, et al.
Annals of the Rheumatic Diseases|July 16, 2008
Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockadeT Cantaert, L De Rycke, C P Mavragani, et al.
Pageof 2